What The Study Did: This randomized clinical trial of patients with severe COVID-19 was stopped early after results from another trial were released but this study investigated whether intravenous hydrocortisone (administered either as a seven-day fixed-dose course or restricted to when shock is clinically evident) improved 21-day organ support-free days.
Authors: Derek C. Angus, M.D., M.P.H., of the University of Pittsburgh, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2020.17022)
Editor's Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17022?guestAccessKey=23fa39bc-68d3-4d4a-88ef-37c908849a05&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090220
JAMA